Compare Merck & Co., Inc. (MRK) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Nutrien Ltd — how do they compare? Merck & Co., Inc. trades at $146.29 (market cap $351.28B), while Nutrien Ltd trades at $67.48 (market cap $33.31B). The key difference: Merck & Co., Inc. is far larger — about 10.5× Nutrien Ltd's market cap, and Nutrien Ltd pays the higher dividend (3.15%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Nutrien Ltd for 59 Days on average.
| MRK | NTR | |
|---|---|---|
Market Cap | $351.28B | $33.31B |
Volume | 7,969,665 | 1,330,729 |
Sector | Health | Basic Materials |
52-Week High | $156.43 | $83.94 |
52-Week Low | $82.49 | $53.64 |
Typical Hold Time | 98 Days | 59 Days |
Enterprise Value | $398.04B | $45.11B |
Dividend Yield | 2.39% | 3.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
NTR trades at $67.48, down 3.56% over 24 hours, with technical indicators showing a bearish trend. The company reported mixed quarterly earnings, missing Q4 2025 and Q2 2026 EPS estimates but beating in Q1 2026. Financials show a net income margin of 8.44% for 2025, with revenue of $26.89B, while recent news highlights industry headwinds from potential U.S. potash deals with Belarus.
The outlook is cautious; analyst consensus is a Moderate Buy with a $76.14 price target, but near-term risks include volatile fertilizer prices and competitive pressures. Long-term demand for agricultural inputs supports fundamentals, yet investors face cyclical earnings and margin compression risks amid macroeconomic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
